Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT03635021
Title Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer (CR-SEQUENCE)
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements Yes
Sponsors Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

rectum adenocarcinoma

colon adenocarcinoma


Fluorouracil + Irinotecan + Leucovorin + Panitumumab

Bevacizumab + Fluorouracil + Leucovorin + Oxaliplatin

Bevacizumab + Fluorouracil + Irinotecan + Leucovorin

Fluorouracil + Leucovorin + Oxaliplatin + Panitumumab

Age Groups: adult | senior
Covered Countries ESP

Additional content available in CKB BOOST